A Case of Severe Acute Cardiac Failure on Sunitinib After Left‐Sided Thoracal Radiation Therapy

[1]  C. Porta,et al.  Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma , 2015, British Journal of Cancer.

[2]  J. Manola,et al.  Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805 , 2015, Clinical Cancer Research.

[3]  G. Demetri,et al.  Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib , 2015, Cancer.

[4]  E. Grande,et al.  Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice , 2015, Endocrine.

[5]  Yang Yao,et al.  Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta‐analysis of 36 clinical trials , 2014, British journal of clinical pharmacology.

[6]  P. Fasching,et al.  Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Channon,et al.  Angiogenesis in the infarcted myocardium. , 2013, Antioxidants & redox signaling.

[8]  Sigal,et al.  Neuroendokrine Neoplasiendes gastroenteropankreatischen Systems , 2012 .

[9]  B. Slotman,et al.  Combining angiogenesis inhibition and radiotherapy: a double-edged sword. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[10]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Srinivas,et al.  Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate , 2008 .

[12]  J. Machiels,et al.  Acute cardiac failure after sunitinib. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  G. Demetri,et al.  Molecular basis for sunitinib efficacy and future clinical development , 2007, Nature Reviews Drug Discovery.

[14]  Nathan C Frey,et al.  Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib , 2007, Clinical Research in Cardiology.

[15]  B. Wiedenmann,et al.  [Gastroenteropancreatic neuro-endocrine neoplasms]. , 2012, Therapeutische Umschau. Revue thérapeutique.

[16]  P. Russo.  Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma , 2009 .

[17]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[18]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.